Quick Facts: Quantrel Therapeutic Domains

• Pinworm (Enterobiasis): May be used to address infections caused by this common parasitic organism.
• Roundworm (Ascariasis): Provides support in the management of this intestinal parasitic condition.
• Hookworm: Is indicated for the treatment of certain hookworm infections.

Quantrel is a medication primarily focused on the management of specific parasitic infections affecting the gastrointestinal tract. Its core utility is based on its established use as an anthelmintic agent.

The medication is intended to provide support in clearing infections, particularly those caused by common roundworms (Ascaris lumbricoides). It is also recognized for its beneficial effect in addressing pinworm infections (Enterobius vermicularis), a condition often requiring household-wide treatment to prevent re-establishment.

Additionally, Quantrel is used to treat certain types of hookworm infections (e.g., Necator americanus and Ancylostoma duodenale). Consulting a healthcare professional is necessary to determine if this medication is the appropriate course of action for a specific diagnosis and to receive detailed instruction for use. The medication may be considered part of a comprehensive therapeutic plan for patients diagnosed with these parasitic conditions.

This section outlines the official eligibility and exclusion criteria for cangrelor (Quantrel/KENGREAL), strictly based on governmental regulatory documents from agencies like the FDA and EMA.

Contraindications (Who Must Not Use)

• Significant Active Bleeding: Use is absolutely prohibited in patients experiencing any significant active bleeding.
• Hypersensitivity: Contraindicated in patients with a known severe allergy (e.g., anaphylaxis) to the drug or any component.
• History of Stroke or TIA: The European label (EMA) additionally prohibits use in patients with any history of stroke or transient ischaemic attack (TIA).

Eligibility and Specific Population Rules

Category	Regulatory Status
Age Groups	Approved for adults; safety and efficacy have not been established in the pediatric population (<18 years). No dose adjustment is required for older adults.
Renal Impairment	Caution is required for those with severe renal impairment (CrCl <30 mL/ min), as a higher rate of worsening kidney function was reported in trials. No dose change is required.
Pregnancy/Lactation	No available data to evaluate drug-associated risk in pregnant women. It is unknown if the drug is present in breast milk, and a risk to the infant cannot be excluded.

These criteria define the official boundaries for use, establishing that exclusion is primarily based on current high bleeding risk and known allergies.

The official interaction profile for Quantrel (Oxantel and Pyrantel Pamoate) focuses on specific constraints involving other medicines, certain substances, and defined patient populations, as strictly outlined in regulatory documentation.

Contraindicated Drug-Drug Interactions

The combination of Quantrel with the anthelmintic medicine Piperazine is formally classified as a contraindication. This is due to a documented pharmacodynamic antagonism where Piperazine diminishes the therapeutic action of Quantrel, which may result in treatment failure. This combination is explicitly prohibited in the official prescribing information.

Exposure Modification and Substance Interactions

A documented pharmacokinetic interaction exists with Theophylline. Co-administration may lead to an increase in the plasma concentration of Theophylline, necessitating caution. Additionally, a substance-related constraint is noted: the co-ingestion of alcohol may potentially exacerbate central nervous system effects, specifically dizziness. There are no officially documented food interactions or mandatory timing rules requiring separation of administration from other medicines.

Condition-Specific Restriction

The regulatory labeling includes a specific, interaction-related restriction for patients with pre-existing liver disease or hepatic impairment. This condition represents a cautionary constraint on the use of Quantrel. The overall interaction scope is limited to these defined drug, substance, and population-based constraints.

Quantrel is a fixed-dose combination product containing pyrantel and oxantel. The primary site of action for both compounds is the nematode organism residing in the gastrointestinal tract. Systemic absorption of the combination is minimal, concentrating the activity locally in the intestinal lumen.

Pyrantel acts as a depolarizing neuromuscular-blocking agent. It functions as an agonist at the nicotinic acetylcholine receptors (nAChRs) on the somatic muscle cells of the susceptible nematodes. This persistent activation leads to excessive depolarization of the muscle membrane, initiating a sustained, spastic paralysis of the worm.

Oxantel also interacts with nematode nAChRs, particularly those subunits preferentially expressed in Trichuris trichiura. This interaction similarly induces depolarization and subsequent neuromuscular blockade. A secondary mechanism involves interference with helminth glycolytic pathways and energy metabolism.

Both induced paralytic states abolish the organism's ability to maintain attachment to the host intestinal wall, leading to passive expulsion from the system via normal intestinal peristalsis.

How to Use Quantrel

The usage of the fixed-dose combination of Oxantel and Pyrantel is guided by prescribing information that defines a precise, single-dose administration protocol. This approach structures the treatment as a one-time event, rather than a prolonged regimen. Quantrel is approved for oral administration and is available as an oral suspension or in tablet form.

---

Official Administration Protocol

The required dose is based on the patient's body weight. The standard calculation is 11 mg of Pyrantel base per kg of body weight, with the maximum total dose not exceeding 1 gram (1000 mg) of Pyrantel base. The instructions state that the medication may be taken with or without food and at any time of day, without the need for prior use of a laxative. The medication should only be administered one time as a single dose; repetition is not permitted unless specifically directed by a healthcare professional.

---

Procedural and Population Rules

For the liquid oral suspension, the container must be shaken well before use, and an accurate, calibrated device is required to ensure the precise volume corresponding to the calculated weight-based dose is measured. The medication is not directed for administration to children under 2 years of age or weighing less than 25 lbs. Furthermore, the overall administration strategy for certain parasitic infections often requires simultaneous treatment of the entire household to ensure the protocol is carried out within the proper public health context.

Research Evidence / Overview of Studies for Quantrel

Quantrel, a fixed-dose combination of Oxantel and Pyrantel, was studied for specific parasitic conditions affecting the intestines. The evidence describing its clinical evaluation comes primarily from Randomized Controlled Trials (RCTs) and systematic reviews that analyze the results of many studies collectively. The focus of this research is on measuring the parasitological outcomes following the study intervention, particularly in communities where these infections are common.

---

Evidence for Use in Roundworm Infections (Ascaris lumbricoides)

The research base for the combination was evaluated in studies primarily involving clinical trials and short-term RCTs for roundworm. These studies were evaluated in populations including school-aged children and adults, and research examined a primary outcome known as the Parasitological Cure Rate (CR), which assesses whether parasite eggs are no longer found in stool samples after the study period. Another key measure was observed in these studies, the Egg Reduction Rate (ERR), which quantifies the number of eggs counted in the stool.

Studies monitored how patient-reported outcomes describing perceived discomfort evolved in the observed populations and described patterns where Cure Rates were reported as a key measurement point across various short-term observation periods. Follow-up durations were limited, typically lasting only a few weeks after the study intervention, which means limited information for long-term outcomes is available.

---

Evidence for Use in Whipworm Infections (Trichuris trichiura)

The combination product was studied for whipworm infections primarily through clinical trials designed to be comparative. Researchers assessed the Cure Rate and the Egg Reduction Rate for this specific organism. Studies report patterns related to measured parasitological outcomes. However, the data show patterns related to outcomes that were mixed and varied across studies depending on the specific regimen and the population being observed. The evidence quality varies across studies, and the interpretation of results can be complicated by the heterogeneity of the trial designs.

---

Key Limitations and Areas of Research Uncertainty

The broader evidence landscape describes several key limitations. Follow-up durations were limited, restricting understanding of long-term outcomes. Evidence quality varies across studies, especially for less common indications. Data for certain groups remain insufficient, particularly for some subgroups outside of the primary focus on school-aged children, and subgroup findings are uncertain.

Common questions about Quantrel (FAQ)

Q: Are there any serious side effects associated with Quantrel mentioned in official documents?

Official regulatory information indicates that most adverse reactions associated with this medicine are mild and temporary. However, events such as transient elevations in liver enzyme values have been reported. Official documents note that patients with pre-existing liver conditions or impairment require caution.

---

Q: What are the signs of an allergic reaction to Quantrel?

Quantrel is strictly contraindicated for anyone with a known allergy or hypersensitivity to its ingredients. Signs of a severe allergic reaction listed in regulatory sources include a skin rash, itching, swelling of the face, tongue, or throat, or having trouble breathing.

---

Q: Is there a list of major drug classes that should not be combined with Quantrel?

Official prescribing information lists specific interactions and constraints. The use of Quantrel is contraindicated with the anthelmintic medicine Piperazine because combining them may diminish Quantrel's therapeutic effect. Additionally, official documents indicate that co-administration with Theophylline necessitates caution.

---

Q: Are there any special considerations for people who drive or operate heavy machinery while taking Quantrel?

Adverse reactions listed in official documents include dizziness and drowsiness. The presence of these side effects means that the regulatory label requires caution before engaging in activities like driving or operating heavy machinery that requires alertness.

---

Q: Is Quantrel the same as the generic version?

Quantrel is the brand name for a medicine containing the active ingredients Oxantel and Pyrantel. According to regulatory guidelines for generics, an approved generic version must be the same as the brand-name medicine in terms of strength, safety, quality, and intended use.

---

Q: Does Quantrel cause weight gain or weight loss?

Official adverse reaction reports list anorexia (loss of appetite) as a documented gastrointestinal effect. However, explicit statements about generalized weight gain or weight loss are not listed in the key adverse reaction categories in official documents.

---

Q: Is there a risk of dependence or withdrawal symptoms with Quantrel?

Regulatory labeling for this medicine does not classify it as a controlled substance. Because of its single-dose use and mechanism, official documents do not mention or document a risk of dependence or withdrawal symptoms associated with its administration.

---

Q: Does Quantrel have a Black Box Warning, and what does it mean?

Official U.S. regulatory labeling for Quantrel does not include a Boxed Warning, which is sometimes referred to as a Black Box Warning. This Boxed Warning is the FDA's strongest safety measure, used specifically to call attention to serious or potentially life-threatening risks associated with a medicine.

---

Q: Can Quantrel be taken with common over-the-counter pain relievers?

While there are no general contraindications, official information on the active ingredient Pyrantel notes that its excretion from the body can be affected by some non-prescription medicines. This includes certain common pain relievers, which could lead to higher levels of the drug remaining in the system.

---

Q: Does grapefruit or grapefruit juice interact with Quantrel?

The official regulatory label states that there are no officially documented food or substance interactions that require specific timing or dietary changes. This general statement covers the consumption of grapefruit and grapefruit juice alongside the medicine.

---

Q: Does Quantrel interact with birth control pills?

Official regulatory labeling does not document a specific interaction between Quantrel and oral hormonal contraceptives, also known as birth control pills.

---

Q: Can Quantrel be taken with vitamins or herbal products?

General safety practice outlined in regulatory resources describe the requirement to disclose all substances taken to a healthcare professional. This includes any vitamins, nutritional supplements, and herbal products to allow for a full evaluation of potential interactions.

---

Q: How long does it typically take for Quantrel to start working?

While the drug acts locally in the intestines, pharmacological information on the active ingredient, Pyrantel, indicates that its peak concentration in the bloodstream typically occurs 1 to 3 hours after administration.

---

Q: What is the expected duration of effect after taking a dose of Quantrel?

The medicine is designed for a single-dose administration and acts primarily locally on the parasites within the gastrointestinal tract. Because of its poor systemic absorption (meaning little of the drug enters the bloodstream), its therapeutic action is concentrated locally for the short period needed to expel the paralyzed parasites.

---

Q: Can the effectiveness of Quantrel decrease over time (tolerance)?

Since Quantrel is approved for a single-dose administration, it is used as a one-time treatment protocol. Therefore, the concept of developing tolerance, which is a decrease in effectiveness over a prolonged period of use, is not applicable to its recommended administration.

---

Q: Can individuals with existing heart problems use Quantrel?

Official regulatory documents state that Quantrel is contraindicated (prohibited) for patients who have a history of stroke or transient ischaemic attack (TIA). The label does not provide a single, generalized statement regarding all other types of heart problems.

---

Q: Where can I find the official prescribing information for Quantrel?

The Official Prescribing Information (PI), often called the package insert, is the full, regulatory document that contains all approved information about the medicine. This document is maintained and published by government agencies such as the FDA on databases like DailyMed, or is available on the websites of bodies like the EMA or MHRA.

Storage and Disposal Requirements

Quantrel must be stored according to regulatory labeling to maintain its stability and effectiveness. The medicine should be kept at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C.

Mandatory Storage Conditions:

• Protect the medicine from both moisture and direct light by keeping it in its original outer carton or container.
• Do not freeze the product, as this can compromise the formulation. Do not expose it to excessive heat.
• Keep the container tightly closed to prevent environmental exposure.
• Store Quantrel out of the sight and reach of children.

Disposal Instructions:

• Expired or unused Quantrel should not be disposed of in household trash or poured down a sink or toilet, unless the label specifically instructs otherwise.
• The official disposal method involves using a medicine take-back program or an authorized collection site to prevent environmental contamination and accidental exposure. Consult local regulations for approved pharmaceutical waste procedures.